Mapping potentially inappropriate medications in older adults using the Anatomical Therapeutic Chemical (ATC) classification system.

Beers Criteria Medicare STOPP criteria potentially problematic medications prescribing cascades

Journal

Journal of the American Geriatrics Society
ISSN: 1532-5415
Titre abrégé: J Am Geriatr Soc
Pays: United States
ID NLM: 7503062

Informations de publication

Date de publication:
20 Dec 2023
Historique:
revised: 09 08 2023
received: 24 04 2023
accepted: 28 08 2023
medline: 21 12 2023
pubmed: 21 12 2023
entrez: 21 12 2023
Statut: aheadofprint

Résumé

Potentially inappropriate medications (PIMs) in older adults are medications in which risks often outweigh benefits and are suggested to be avoided. Worldwide, many distinct guidelines and tools classify PIMs in older adults. Collating these guidelines and tools, mapping them to a medication classification system, and creating a crosswalk will enhance the utility of PIM guidance for research and clinical practice. We used the Anatomical Therapeutic Chemical (ATC) Classification System, a hierarchical classification system, to map PIMs from eight distinct guidelines and tools (2019 Beers Criteria, Screening Tool for Older Person's Appropriate Prescriptions [STOPP], STOPP-Japan, German PRISCUS, European Union-7 Potentially Inappropriate Medication [PIM] list, Centers for Medicare & Medicaid Services [CMS] High-Risk Medication, Anticholinergic Burden Scale, and Drug Burden Index). Each PIM was mapped to ATC Level 5 (drug) and to ATC Level 4 (drug class). We then used the crosswalk (1) to compare PIMs and PIM drug classes across guidelines and tools to determine the number of PIMs that were index (drug-induced adverse event) or marker (treatment of drug-induced adverse event) drug of prescribing cascades, and (2) estimate the prevalence of PIM use in older adults continuously enrolled with fee-for-service Medicare in 2018 as use cases. Data visualization and descriptive statistics were used to assess guidelines and tools for both use cases. Out of 480 unique PIMs identified, only three medications-amitriptyline, clomipramine, and imipramine and two drug classes-N06AA (tricyclic antidepressants) and N06AB (selective serotonin reuptake inhibitors), were noted in all eight guidelines and tools. Using the crosswalk, 50% of classes of index drugs and 47% of classes of marker drugs of known prescribing cascades were PIMs. Additionally, 88% of Medicare beneficiaries were dispensed ≥1 PIM across the eight guidelines and tools. We created a crosswalk of eight PIM guidelines and tools to the ATC classification system and created two use cases. Our findings could be used to expand the ease of PIM identification and harmonization for research and clinical practice purposes.

Sections du résumé

BACKGROUND BACKGROUND
Potentially inappropriate medications (PIMs) in older adults are medications in which risks often outweigh benefits and are suggested to be avoided. Worldwide, many distinct guidelines and tools classify PIMs in older adults. Collating these guidelines and tools, mapping them to a medication classification system, and creating a crosswalk will enhance the utility of PIM guidance for research and clinical practice.
METHODS METHODS
We used the Anatomical Therapeutic Chemical (ATC) Classification System, a hierarchical classification system, to map PIMs from eight distinct guidelines and tools (2019 Beers Criteria, Screening Tool for Older Person's Appropriate Prescriptions [STOPP], STOPP-Japan, German PRISCUS, European Union-7 Potentially Inappropriate Medication [PIM] list, Centers for Medicare & Medicaid Services [CMS] High-Risk Medication, Anticholinergic Burden Scale, and Drug Burden Index). Each PIM was mapped to ATC Level 5 (drug) and to ATC Level 4 (drug class). We then used the crosswalk (1) to compare PIMs and PIM drug classes across guidelines and tools to determine the number of PIMs that were index (drug-induced adverse event) or marker (treatment of drug-induced adverse event) drug of prescribing cascades, and (2) estimate the prevalence of PIM use in older adults continuously enrolled with fee-for-service Medicare in 2018 as use cases. Data visualization and descriptive statistics were used to assess guidelines and tools for both use cases.
RESULTS RESULTS
Out of 480 unique PIMs identified, only three medications-amitriptyline, clomipramine, and imipramine and two drug classes-N06AA (tricyclic antidepressants) and N06AB (selective serotonin reuptake inhibitors), were noted in all eight guidelines and tools. Using the crosswalk, 50% of classes of index drugs and 47% of classes of marker drugs of known prescribing cascades were PIMs. Additionally, 88% of Medicare beneficiaries were dispensed ≥1 PIM across the eight guidelines and tools.
CONCLUSION CONCLUSIONS
We created a crosswalk of eight PIM guidelines and tools to the ATC classification system and created two use cases. Our findings could be used to expand the ease of PIM identification and harmonization for research and clinical practice purposes.

Identifiants

pubmed: 38124261
doi: 10.1111/jgs.18681
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : HSRD VA
ID : IK2 HX003359
Pays : United States
Organisme : NIA NIH HHS
ID : K24 AG049057
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG04428
Pays : United States
Organisme : NIA NIH HHS
ID : R24 AG064025
Pays : United States

Informations de copyright

© 2023 The American Geriatrics Society.

Références

Baruth JM, Gentry MT, Rummans TA, Miller DM, Burton MC. Polypharmacy in older adults: the role of the multidisciplinary team. Hosp Pract (1995). 2020;48:56-62.
Young EH, Pan S, Yap AG, Reveles KR, Bhakta K. Polypharmacy prevalence in older adults seen in United States physician offices from 2009 to 2016. PLoS One. 2021;16:e0255642.
Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC. Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med. 2016;176:473-482.
Hubbard RE, O'Mahony MS, Woodhouse KW. Medication prescribing in frail older people. Eur J Clin Pharmacol. 2013;69:319-326.
Dhalwani NN, Fahami R, Sathanapally H, Seidu S, Davies MJ, Khunti K. Association between polypharmacy and falls in older adults: a longitudinal study from England. BMJ Open. 2017;7:e016358.
Thürmann PA. Pharmacodynamics and pharmacokinetics in older adults. Curr Opin Anaesthesiol. 2020;33:109-113.
Lamy PP. Comparative pharmacokinetic changes and drug therapy in an older population. J Am Geriatr Soc. 1982;30(11 Suppl):S11-S19.
Rakesh KB, Chowta MN, Shenoy AK, Shastry R, Pai SB. Evaluation of polypharmacy and appropriateness of prescription in geriatric patients: a cross-sectional study at a tertiary care hospital. Indian J Pharmacol. 2017;49:16-20.
Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers Criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716-2724.
Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med. 1991;151:1825-1832.
Dimitrow MS, Airaksinen MS, Kivelä SL, Lyles A, Leikola SN. Comparison of prescribing criteria to evaluate the appropriateness of drug treatment in individuals aged 65 and older: a systematic review. J Am Geriatr Soc. 2011;59(8):1521-1530.
American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674-694.
Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert Doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46:72-83.
Motter FR, Fritzen JS, Hilmer SN, Paniz ÉV, Paniz VMV. Potentially inappropriate medication in the elderly: a systematic review of validated explicit criteria. Eur J Clin Pharmacol. 2018;74:679-700.
Tannenbaum C, Farrell B, Shaw J, et al. An ecological approach to reducing potentially inappropriate medication use: Canadian deprescribing network. Can J Aging. 2017;36:97-107.
Faure R, Dauphinot V, Krolak-Salmon P, Mouchoux C. A standard international version of the Drug Burden Index for cross-national comparison of the functional burden of medications in older people. J Am Geriatr Soc. 2013;61(7):1227-1228.
Mahony DO, Sullivan DO, Byrne S, Connor MNO, Ryan C, Gallagher P. Corrigendum: STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2017;47:489.
Kojima T, Mizukami K, Tomita N, et al. Screening tool for older persons' appropriate prescriptions for Japanese: report of the Japan Geriatrics Society Working Group on “guidelines for medical treatment and its safety in the elderly”. Geriatr Gerontol Int. 2016;16:983-1001.
Holt S, Schmiedl S, Thürmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int. 2010;107:543-551.
Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71:861-875.
Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168:508-513.
Hilmer SN, Mager DE, Simonsick EM, et al. A Drug Burden Index to define the functional burden of medications in older people. Arch Intern Med. 2007;167:781-787.
Kersten H, Wyller TB. Anticholinergic drug burden in older people's brain-how well is it measured? Basic Clin Pharmacol Toxicol. 2014;114:151-159.
Okudur SK, Dokuzlar O, Aydin AE, Kocyigit SE, Soysal P, Isik AT. The evaluation of relationship between polypharmacy and anticholinergic burden scales. North Clin Istanb. 2021;8:139.
Salahudeen MS, Hilmer SN, Nishtala PS. Comparison of anticholinergic risk scales and associations with adverse health outcomes in older people. J Am Geriatr Soc. 2015;63(1):85-90.
Gnjidic D, Cumming RG, Le Couteur DG, et al. Drug Burden Index and physical function in older Australian men. Br J Clin Pharmacol. 2009;68:97-105.
Gnjidic D, Bell JS, Hilmer SN, Lönnroos E, Sulkava R, Hartikainen S. Drug Burden Index associated with function in community-dwelling older people in Finland: a cross-sectional study. Ann Med. 2012;44:458-467.
Pharmacy Quality Alliance. Polypharmacy: Use of Multiple Anticholinergic Medications in Older Adults. Pharmacy Quality Alliance; 2021.
Pharmacy Quality Alliance. Polypharmacy: CNS-Active Medications in Older Adults. Pharmacy Quality Alliance; 2021.
American Medical Association. Quality ID #238 (NQF 0022): Use of High-Risk Medications in the Elderly-National Quality Strategy Domain: Patient Safety. 2019.
World Health Organization. ATC/DDD classification (temporary). WHO Drug Information. 2019;33:226-232.
IBM Micromedex. REDBOOK® (Electronic version). Truven Health Analytics; 2020.
Rønning M, Salvesen Blix H, Tange Harbø B, Strøm H. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose-are drug utilisation data comparable? Eur J Clin Pharmacol. 2000;56:723-727.
McCarthy LM, Visentin JD, Rochon PA. Assessing the scope and appropriateness of prescribing cascades. J Am Geriatr Soc. 2019;67(5):1023-1026.
Brath H, Mehta N, Savage RD, et al. What is known about preventing, detecting, and reversing prescribing cascades: a scoping review. J Am Geriatr Soc. 2018;66(11):2079-2085.
Farrell B, Galley E, Jeffs L, Howell P, McCarthy LM. “Kind of blurry”: deciphering clues to prevent, investigate and manage prescribing cascades. PloS One. 2022;17:e0272418.
Morris EJ, Hollmann J, Hofer A-K, et al. Evaluating the use of prescription sequence symmetry analysis as a pharmacovigilance tool: a scoping review. Res Soc Admin Pharm. 2021;18:3079-3093.
Monnet DL, Mölstad S, Cars O. Defined daily doses of antimicrobials reflect antimicrobial prescriptions in ambulatory care. J Antimicrob Chemother. 2004;53:1109-1111.
Westh H, Zinn CS, Rosdahl VT, Group SS. An international multicenter study of antimicrobial consumption and resistance in Staphylococcus aureus isolates from 15 hospitals in 14 countries. Microb Drug Resist. 2004;10:169-176.
Fialová D, Topinková E, Gambassi G, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA. 2005;293:1348-1358.
Pitkala KH, Strandberg TE, Tilvis RS. Inappropriate drug prescribing in home-dwelling, elderly patients: a population-based survey. Arch Intern Med. 2002;162:1707-1712.
Kunin CM. Inappropriate medication use in older adults: does nitrofurantoin belong on the list for the reasons stated? Arch Intern Med. 2004;164:1701.
Farrell BJ, Jeffs L, Irving H, McCarthy LM. Patient and provider perspectives on the development and resolution of prescribing cascades: a qualitative study. BMC Geriatr. 2020;20:368.
Savage RD, Visentin JD, Bronskill SE, et al. Evaluation of a common prescribing cascade of calcium channel blockers and diuretics in older adults with hypertension. JAMA Intern Med. 2020;180:643-651.
Vouri SM, van Tuyl JS, Olsen MA, Xian H, Schootman M. An evaluation of a potential calcium channel blocker-lower-extremity edema-loop diuretic prescribing cascade. J Am Pharm Assoc (2003). 2018;58:534-539. e534.
Singh S, Cocoros NM, Haynes K, et al. Antidopaminergic-antiparkinsonian medication prescribing cascade in persons with Alzheimer's disease. J Am Geriatr Soc. 2021;69(5):1328-1333.
Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005;165:808-813.
Trenaman SC, Bowles SK, Kirkland S, Andrew MK. An examination of three prescribing cascades in a cohort of older adults with dementia. BMC Geriatr. 2021;21:297.
Bloomstone S, Anzuoni K, Cocoros N, et al. Prescribing cascades in persons with Alzheimer's disease: engaging patients, caregivers, and providers in a qualitative evaluation of print educational materials. Ther Adv Drug Saf. 2020;11:2042098620968310.
Perpétuo C, Plácido AI, Rodrigues D, et al. Prescription of potentially inappropriate medication in older inpatients of an internal medicine ward: concordance and overlap among the EU (7)-PIM list and Beers and STOPP criteria. Front Pharmacol. 2021;12:1768.
Sharma R, Bansal P, Garg R, Ranjan R, Kumar R, Arora M. Prevalence of potentially inappropriate medication and its correlates in elderly hospitalized patients: a cross-sectional study based on Beers Criteria. J Family Community Med. 2020;27:200-207.
Alhawassi TM, Alatawi W, Alwhaibi M. Prevalence of potentially inappropriate medications use among older adults and risk factors using the 2015 American Geriatrics Society Beers Criteria. BMC Geriatr. 2019;19:1-8.
Miller GE, Sarpong EM, Davidoff AJ, Yang EY, Brandt NJ, Fick DM. Determinants of potentially inappropriate medication use among community-dwelling older adults. Health Serv Res. 2017;52:1534-1549.
Chinthammit C, Bhattacharjee S, Lo-Ciganic W-H, et al. Association of low-income subsidy, Medicaid dual eligibility, and disability status with high-risk medication use among Medicare Part D beneficiaries. Res Soc Admin Pharm. 2022;18:2634-2642.

Auteurs

Asinamai Ndai (A)

Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, Florida, USA.

Julie Al Bahou (J)

Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, Florida, USA.

Earl Morris (E)

Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, Florida, USA.

Hsin-Min Wang (HM)

Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, Florida, USA.

Zach Marcum (Z)

Department of Pharmacy, University of Washington, Seattle, WA, USA.

Anna Hung (A)

Department of Population Health Sciences, Duke University, Durham, North Carolina, USA.
Duke-Margolis Center for Health Policy, Duke University, Durham, North Carolina, USA.
Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT), Durham Veterans Affairs Health Care System, Durham, North Carolina, USA.

Nicole Brandt (N)

The Peter Lamy Center on Drug Therapy and Aging, University of Maryland, Baltimore, Maryland, USA.

Michael A Steinman (MA)

Division of Geriatrics, Department of Medicine, University of California San Francisco and the San Francisco VA Medical Center, San Francisco, California, USA.

Scott Martin Vouri (SM)

Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, Florida, USA.
Center for Drug Evaluation and Safety, University of Florida, Gainesville, Florida, USA.

Classifications MeSH